Sabby Management’s Larimar Therapeutics LRMR Stock Holding History

Sabby Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-11,943	Closed	-$668K	–	240
2017 Q1	$668K	Sell	11,943 -13,890	-54%	-$690K	0.04%	158
2016 Q4	$986K	Buy	+25,833	New	+$1.05M	0.06%	146
2015 Q1	–	Sell	-9,272	Closed	-$3.43M	–	314
2014 Q4	$3.43M	Sell	9,272 -18,025	-66%	-$4.64M	0.11%	90
2014 Q3	$6.44M	Buy	+27,297	New	+$6.19M	0.25%	53

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Sabby Management's LRMR Position: Q2 2017 in Review

Sabby Management sold out of Larimar Therapeutics (LRMR) in Q2 2017, closing a stake of 11,943 shares — an estimated $668K sold.

Sabby Management first reported a position in LRMR in Q3 2014 and held it in 4 quarters. The position peaked at $6.44M in Q3 2014. 69 funds tracked by Wall St. Rank hold LRMR as of Q2 2017.

Sabby Management reported no remaining Larimar Therapeutics position as of Q2 2017 after selling out during the quarter.
Sabby Management sold 11,943 Larimar Therapeutics shares in Q2 2017, an estimated $668K.
Sabby Management first reported a position in Larimar Therapeutics in Q3 2014 and held it in 4 quarters.
Sabby Management's Larimar Therapeutics position peaked at $6.44M in Q3 2014.
69 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.